Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study - Concepedia

Concepedia

Publication | Open Access

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

DOI Full Paper Access

428

Citations

27

References

2021

Year

Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel S.W. Tan,

The Lancet Oncology

Abstract

Blueprint Medicines.

References

	Year	Citations

Page 1